ライフサイエンスコーパス: abdominal infection

1 one site of infection (eg, pneumonia, intra-abdominal infection).

2 re unit patients requiring surgery for intra-abdominal infection.

3 rms of age and gender as well as the site of abdominal infection.

4 to induce abscesses in a rat model of intra-abdominal infection.

5 useful adjunct in treating hepatic and intra-abdominal infections.

6 ical intensive care unit patients with intra-abdominal infections.

7 lms in the gastrointestinal tract, and intra-abdominal infections.

8 eriority of short-duration therapy for intra-abdominal infections.

9 arly in those with early posttransplantation abdominal infections.

10 s: 10 with wound infections and 2 with intra-abdominal infections.

11 vity against pathogens associated with intra-abdominal infections.

12 infants with suspected or complicated intra-abdominal infections.

13 may benefit a subset of patients, those with abdominal infections.

14 d D. vulgaris has been associated with intra-abdominal infections.

15 provides a clear abdominal field for imaging abdominal infections.

16 ilastatin for treatment of complicated intra-abdominal infections.

17 openem in the treatment of complicated intra-abdominal infections.

18 most common interventions were performed for abdominal infection (31.7%; RR mortality = 2.9; 95% CI =

19 e days 2, 3, 4, and/or 5 as markers of intra-abdominal infection after elective colorectal surgery.

20 ng the risk of increased postoperative intra-abdominal infections after laparoscopic appendectomy, th

21 infections without any prior surgery, 7 had abdominal infections after surgery, 4 had perianal absce

22 , 30-day readmission rates, ileus, and intra-abdominal infection (all P's > .05).

23 12 for urinary tract infection, 83 for intra-abdominal infection and 45 for bloodstream infection.

24 reinsertion of nasogastric tube), and intra-abdominal infection and association between colorectal c

25 ker for the detection of postoperative intra-abdominal infection and the appropriate moment to measur

26 fter bariatric surgery whereas that of intra-abdominal infection and UTI increased.

27 tcome in community-acquired pneumonia, intra-abdominal infections and bloodstream infections, respect

28 ons by logistic regression analysis, and for abdominal infections and pneumonia using matched control

29 After matching patients with abdominal infections and pneumonia with BSI to patients

30 act infection and ten with complicated intra-abdominal infection) and 148 assigned to best available

31 nvasive disease, such as endocarditis, intra-abdominal infection, and shock.

32 Twenty-four-hour transfusions, abdominal infections, and hospital length of stay were a

33 aneurysm formation, anastomotic leaks, intra-abdominal infections, and, al. though rare, AVF.

34 0- to 12-month postsurgery period for intra-abdominal infection (aOR, 2.09 [95% CI, 1.78-2.46]) and

35 emergency gastrointestinal surgery for intra-abdominal infection are at risk of invasive candidiasis

36 Intra-abdominal infections are common in young infants and lea

37 Intra-abdominal infections are frequent and life-threatening c

38 Intra-abdominal infections are one of the most common infectio

39 han procalcitonin for the detection of intra-abdominal infection (areas under the ROC curve: 0.775 vs

40 In clinical trials of complicated intra-abdominal infections, assessment of adequacy of the init

41 fference in time to first infection or first abdominal infection between groups.

42 atory cytokine production during acute intra-abdominal infection caused by cecal ligation and punctur

43 urinary tract infection or complicated intra-abdominal infection caused by ceftazidime-resistant Ente

44 al trials in patients with complicated intra-abdominal infections (cIAI).

45 ce among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of

46 hospitalized patients with complicated intra-abdominal infections (cIAIs).

47 onsensus Criteria) due to pneumonia or intra-abdominal infection (cohorts 1-3, n=2534 patients).

48 Intra-abdominal infection decreased from 7.4% to 2.5% (P = .24

49 r operative management in terms of decreased abdominal infections, decreased transfusions, and decrea

50 Recurrent intra-abdominal infection developed in 15 patients, but only 1

51 urinary tract infection or complicated intra-abdominal infection due to ceftazidime-resistant Gram-ne

52 hest during natural disaster missions, intra-abdominal infections during hospital support missions, a

53 is rodent model of antibiotic-treated, intra-abdominal infection features key characteristics of clin

54 in 1066 men and women with complicated intra-abdominal infections from 2 identical, randomized, doubl

55 ays of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensi

56 rbidity after liver transplantation is intra-abdominal infection (IAI) about which there are limited

57 Candida albicans-Staphylococcus aureus intra-abdominal infection (IAI) results in 100% mortality by 4

58 Intra-abdominal infections (IAIs) after elective colorectal su

59 l trials of antibiotics in complicated intra-abdominal infections identified through systematic revie

60 hreatening disease via bloodstream and intra-abdominal infections in immunocompromised and transplant

61 These data suggest that severe polymicrobial abdominal infection induces prothrombotic FXI activation

62 ndromes, including urinary tract infections, abdominal infections, nosocomial pneumonia, neonatal men

63 omplications such as graft thrombosis, intra-abdominal infection, or abscess were reported.

64 fection (SSTI), respiratory infection, intra-abdominal infection, or urinary tract infection (UTI).

65 ic therapy for patients with localized intra-abdominal infections ranging from mild to moderate sever

66 Intra-abdominal infections result in substantial morbidity, mo

67 Staphylococcus aureus-Candida albicans intra-abdominal infection results in approximately 60% mortali

68 short-course antimicrobial therapy for intra-abdominal infection (STOP-IT), and results suggest globa

69 ntigen-induced shock and polymicrobial intra-abdominal infection, supporting its potential use in cli

70 5 anti-infective agents in complicated intra-abdominal infections used a source control review proces

71 The incidence of intra-abdominal infection was 11.8%, with 24.6% of patients pr

72 Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) was a prospective, randomized, dou

73 ients with sepsis due to pneumonia and intra-abdominal infection were combined.

74 nor (76%), whereas most operations for intra-abdominal infections were major (98%).

75 Retransplantation and intra-abdominal infections were major risk factors.

76 ract infection and 11 with complicated intra-abdominal infection) were analysed for the primary outco

77 inary tract infections and complicated intra-abdominal infections (when used with metronidazole).

78 ) mice were generated and subjected to intra-abdominal infection with Klebsiella pneumoniae, which re

79 wo patients had bacteremic infections, 4 had abdominal infections without any prior surgery, 7 had ab

80 complicated urinary tract infections, intra-abdominal infections), yet these designs may not be opti